US2019359575A1PendingUtilityA1

Dihydropyrimidin-2-one compounds and medical use thereof

59
Assignee: JAPAN TOBACCO INCPriority: Dec 12, 2014Filed: Dec 20, 2018Published: Nov 28, 2019
Est. expiryDec 12, 2034(~8.4 yrs left)· nominal 20-yr term from priority
Inventors:Masahiro YokotaTaku IkenogamiEiichi WatanabeNoriyoshi SekiTakayuki SakaiShingo FujiokaMakoto ShiozakiKatsunori SuwaYosuke OgoshiMasato NoguchiKatsuya Maeda
A61P 29/00C07D 239/22C07D 405/04A61P 43/00A61K 31/506C07D 401/04A61K 31/695A61P 3/00C07F 7/0812C07D 405/10C07F 7/12C07D 403/04A61P 37/00A61P 25/00C07D 413/04A61P 17/00A61K 31/505A61P 27/00C07D 403/06C07D 239/36A61P 37/06A61P 19/08A61P 19/04A61P 3/10A61P 19/02A61P 17/06A61P 1/04C07C 275/06C07C 265/02
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

wherein each symbol is defined as in the specification.

Claims

exact text as granted — not AI-modified
1 - 37 . (canceled) 
     
     
         38 : A method of inhibiting RORγ, comprising administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         39 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         40 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         41 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         42 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         43 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         44 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       a pharmaceutically acceptable salt thereof. 
     
     
         45 : The method of  claim 38 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         46 : A method of treating a disease selected from the group consisting of allergic disease, dry eye, fibrosis, and metabolic disease, comprising administering to a mammal an effective amount of a compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         47 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         48 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         49 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         50 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         51 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         52 : The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         53 . The method of  claim 46 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         54 : The method according to any one of  claims 46  to  53 , wherein the disease is allergic disease. 
     
     
         55 : The method according to any one of  claims 46  to  53 , wherein the disease is dry eye. 
     
     
         56 : The method according to any one of  claims 46  to  53 , wherein the disease is fibrosis. 
     
     
         57 : The method according to any one of  claims 46  to  53 , wherein the disease is metabolic disease.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.